Related Experiment Video
Updated: Dec 12, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
A New Inhibitor of Tubulin Polymerization Kills Multiple Cancer Cell Types and Reveals p21-Mediated Mechanism
Mykola Zdioruk1, Andrew Want1, Anna Mietelska-Porowska1
1Laboratory of Preclinical Testing of Higher Standards, Nencki Institute of Experimental Biology, Polish Academy of Science, 02-093 Warsaw, Poland.
Abstract:
Induction of mitotic catastrophe through the disruption of microtubules is an established target in cancer therapy. However, the molecular mechanisms determining the mitotic catastrophe and the following apoptotic or non-apoptotic cell death remain poorly understood. Moreover, many existing drugs targeting tubulin, such as vincristine, have reduced efficacy, resulting from poor solubility in physiological conditions. Here, we introduce a novel small molecule 2-aminoimidazoline derivative-OAT-449, a synthetic water-soluble tubulin inhibitor. OAT-449 in a concentration range from 6 to 30 nM causes cell death of eight different cancer cell lines in vitro, and significantly inhibits tumor development in such xenograft models as HT-29 (colorectal adenocarcinoma) and SK-N-MC (neuroepithelioma) in vivo. Mechanistic studies showed that OAT-449, like vincristine, inhibited tubulin polymerization and induced profound multi-nucleation and mitotic catastrophe in cancer cells. HeLa and HT-29 cells within 24 h of treatment arrested in G2/M cell cycle phase, presenting mitotic catastrophe features, and 24 h later died by non-apoptotic cell death. In HT-29 cells, both agents altered phosphorylation status of Cdk1 and of spindle assembly checkpoint proteins NuMa and Aurora B, while G2/M arrest and apoptosis blocking was consistent with p53-independent accumulation in the nucleus and largely in the cytoplasm of p21/waf1/cip1, a key determinant of cell fate programs. This is the first common mechanism for the two microtubule-dissociating agents, vincristine and OAT-449, determining the cell death pathway following mitotic catastrophe demonstrated in HT-29 cells.
Insights
A novel water-soluble tubulin inhibitor, OAT-449, effectively induces mitotic catastrophe and cancer cell death. This agent shares a p53-independent cell death mechanism with vincristine, offering a promising cancer therapy avenue.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Microtubule disruption via mitotic catastrophe is a cancer therapy target.
- Mechanisms of mitotic catastrophe and subsequent cell death are not fully understood.
- Existing tubulin inhibitors like vincristine have poor solubility and reduced efficacy.
Purpose of the Study:
- To introduce and characterize a novel, water-soluble tubulin inhibitor, OAT-449.
- To investigate the molecular mechanisms of OAT-449-induced cancer cell death.
- To compare OAT-449's mechanism with that of vincristine.
Main Methods:
- In vitro testing on eight cancer cell lines.
- In vivo xenograft models (HT-29, SK-N-MC).
- Analysis of tubulin polymerization, cell cycle arrest, protein phosphorylation (Cdk1, NuMa, Aurora B), and p21/waf1/cip1 localization.
Main Results:
- OAT-449 (6-30 nM) induced cell death in vitro and inhibited tumor growth in vivo.
- OAT-449 inhibited tubulin polymerization, causing multi-nucleation and mitotic catastrophe.
- Both OAT-449 and vincristine induced G2/M arrest, non-apoptotic cell death, and altered protein phosphorylation in a p53-independent manner.
Conclusions:
- OAT-449 is a potent, water-soluble tubulin inhibitor with anticancer activity.
- OAT-449 induces mitotic catastrophe and non-apoptotic cell death.
- A shared p53-independent mechanism involving p21/waf1/cip1 regulates cell fate after mitotic catastrophe induced by OAT-449 and vincristine.
Related Concept Videos
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules
Negative Regulator Molecules
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle

